Clinical variants of <i>TARDBP</i> are associated with frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and other degenerative diseases. The predicted <i>C. elegans</i> ortholog of <i>TARDBP</i> is encoded by <i>
tdp-1</i> , but functional orthology has not been demonstrated <i>in vivo.</i> We undertook CRISPR/Cas9-based genome editing of the <i>
tdp-1</i> locus to create a complete loss of function allele; all <i>
tdp-1</i> exons and introns were deleted, creating <i>
tdp-1(
tgx58)</i> , which resulted in neurodegeneration after oxidative stress. Next, we undertook CRISPR-based genome editing to replace <i>
tdp-1</i> exons with human TARDBP coding sequences, creating humanized ( <i>hTARDBP</i> ) <i>C. elegans</i> expressing TDP-43 <i>.</i> Based on the efficiency of this genome editing, we suggest that iterative genome editing of the <i>
tdp-1</i> target locus using linked coCRISPR markers, like <i>
dpy-10</i> , would be a more efficient strategy for sequential assembly of the large engineered transgenes. <i>hTARDBP</i> decreased the neurodegeneration defect of <i>
tdp-1(
tgx58)</i> , demonstrating functional cross-species orthology. To develop <i>C. elegans</i> models of FTD and ALS, we inserted five different patient <i>TARDBP</i> variants in the <i>C. elegans</i> <i>hTARDBP</i> locus. Only one clinical variant increased stress-induced neurodegeneration; other variants caused inconsistent or negligible defects under these conditions. Combined, this work yielded an unambiguous null allele for <i>
tdp-1</i> , a validated, humanized <i>hTARDBP,</i> and multiple ALS/FTD patient-associated variant models that can be used for future studies.